Draupnir Bio
draupnir.bio
Actively hiring
Neurology & CNS Therapeutics
Drug Discovery
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$13M
1 round on record
Latest round
$13M
Seed · Jul 2024 · 2 yr ago
Backers
1
Inkef
The money's age
Long since its last round
26 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 17, 2024
Raised a round Seed $13M · YahooFinance
Jun 23, 2021
New executive Andrew Hotchkiss joins Draupnir Bio as Chief Executive Officer · stockhouse.com
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Seed | Jul 2024 | $13M | — | YahooFinance |
Backed byfrom the funds' portfolios and accelerator catalogs
Inkef Similar startupsby what they do, their industry and backers
Damona Pharmaceuticals is developing precision neuromedicines to reverse cognitive deficits associated with brain disorders.associated with…
Developing transformative medicines for neurological and mental health disorders.
Brenig Therapeutics develops innovative small-molecule therapies for neurodegenerative diseases, including LRRK2 inhibitors targeting…
0 Enable better lives through novel therapies to restore skeletal muscle health About NMD Pharma NMD Pharma is a clinical-stage biotech…
Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular…
Variant Bio is developing life-saving therapies by studying the genes of people with exceptional health-related traits.
News
PCSK9 inhibitors reported in Draupnir Bio patent
Work at Draupnir Bio ApS has led to the identification of new proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors potentially useful for the treatment of coronary heart disease and dyslipidemia.
Read more
Report
Draupnir Bio announces transformational publication detailing extracellular targeted protein degradation technology in Cell Chemical Biology
Draupnir's novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targetsStudy further details platform versatility through successful degradatio
Read more
Report
Draupnir Bio Institution outputs
The Nature Index tracks the affiliations of high-quality scientific articles. Updated monthly, the Nature Index presents research outputs by institution and country. Use the Nature Index to interrogate publication patterns and to benchmark research perfor
Read more
Report
Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins
Draupnir Bio completes €12 million seed round to progress development of oral small molecule degraders of extracellular proteins MP Healthcare and EIFO join existing investors, Gilde Healthcare Partners, Inkef Capital and Novo Holdings Copenhagen, Denmark
Read more
Report
Draupnir Bio Institution outputs
The Nature Index tracks the affiliations of high-quality scientific articles. Updated monthly, the Nature Index presents research outputs by institution and country. Use the Nature Index to interrogate publication patterns and to benchmark research perfor
Read more
Report
Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease
Press Release Draupnir Bio establishes Scientific Advisory Board of European experts in cholesterol metabolism and cardiovascular disease Copenhagen, Denmark, 23 September 2021 -
Read more
Report
Draupnir Bio strengthens senior management with the appointment of Anna Quattropani as Chief Discovery Officer
Press Release Draupnir Bio strengthens senior management with the appointment of Anna Quattropani as Chief Discovery Officer Copenhagen, Denmark, 12 July 2021 - Draupnir Bio (
Read more
Report
Financials
Total raised
$13M
Latest round
Seed
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Seed | 2024 | $13M | Details |